Key Points Participants in a maintenance study of VK2735 maintained up to 97% of their weight loss after 12 weeks. The global obesity drug market could grow to $150 billion by 2035. 10 stocks we like better than Viking Therapeutics › Shares of Viking Therapeutics (NASDAQ: VKTX) surged on Tuesday after the biopharmaceutical specialist announced encouraging clinical trial results for its experimental weight loss drug. Image source: Getty Images. Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.